AnaptysBio Stock Down as Eczema Study Fails to Meet Goals
Shares of AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the phase IIb study of pipeline candidate, ANB032, a BTLA agonist, was unsuccessful.
AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated
Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking the stock’s steepest single-day loss since March 2021. The collapse followed the company’s announcement that it would halt further investment in its experimental therapy ANB032 after the drug failed to meet primary and
AnaptysBio to abandon eczema drug development after mid-stage trial failure
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 40% lower.
AnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares Fall
The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, often referred to as eczema.
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema.
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...
FierceBiotech1d
AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
clinicaltrialsarena6h
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints
AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.
The Pharma Letter22h
AnaptysBio drops development of ANB032 following trial miss
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...
AnaptysBio announces Phase 2b trial of ANB032 did not meet primary endpoint
AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses ...
Seeking Alpha20d
AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching
The near-term catalysts include a Phase 2b trial for the drug candidates rosnilimab and ANB032, which are crucial for re-evaluating AnaptysBio’s stock value. Despite this promising pipeline and ...
Yahoo Finance1mon
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024 Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid ...